Report: Alexion allies with Goldman as Roche buyout rumor blazes

John Carroll If Roche actually comes through with a $ 22 billion-plus bid for Alexion, the biotech intends to be ready to man the defenses and fight it out for top dollar. FierceBiotech ...

Moody’s cuts GlaxoSmithKline outlook, citing billions in outlays

Tracy Staton As if GlaxoSmithKline didn't have enough trouble on its hands, Moody's Investors Service has cast some dark clouds over its credit outlook. The agency cut the outlook ...

Tweets of the day, 7/30/2013

chris.truelove by Christiane Truelove (chris.truelove@ubm.com) Quite a lot of news has happened. We have Pfizer announcing mixed results for the second quarter as the company is creating ...

Novartis: No data-tampering in retracted Diovan study

Tracy Staton Former Novartis employees did work on Diovan trials in Japan and didn't disclose their relationships with the company in the studies, the company says. But Novartis ...

Stereotaxis Receives FDA Clearance of Vdrive With V-Sono System

barbara.lempert Strengthens Niobe(R) Adoption and Opens Growing ICE Catheter Market to Company ST. LOUIS, July 29, 2013 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (Nasdaq:STXS) announced ...

Is biotech billionaire Kirk’s Intrexon worth $1.4B?

Tracy Staton Intrexon has set terms for a proposed $ 125 million IPO that could value the company at $ 1.4 billion. FiercePharma News

Consumer Awareness Of New Obesity Drugs Remains Low

esilverman There may be a pair of recently approved prescription diet pills available, but is the public paying any attention? Investors are alert if only because they are ...

Is biotech billionaire Kirk’s Intrexon worth $1.4B?

Ryan McBride Germantown, MD-based Intrexon, a synthetic biology outfit led by billionaire Randal Kirk, aims to sell 8.3 million shares at a proposed range of $ 14 to $ 16 per share. FierceBiotech ...

Pfizer’s 3-way operational split overshadows ‘solid’ Q2 results

Tracy Staton Pfizer dropped a bombshell yesterday, saying it would reorganize into three distinct business units, each with its own group president and financial reports. The thinking, ...

Sorin Group Announces FDA 510(k) Clearance For The New Sorin Connect Perfusion Charting System

barbara.lempert Milan, July 30, 2013 – Sorin Group, (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today the ...

Perlmutter prunes R&D at Merck amid calls for change

Ryan McBride Merck unveiled lackluster second-quarter earnings on Tuesday, reminding industry watchers of the U.S. drug giant's need for new therapies. The need to renew the company's ...

Suffering from generic onslaught, Merck cuts sales forecast

Tracy Staton Merck cut its sales forecast and posted a 50% drop in quarterly earnings as it continues to absorb major hits to its once-blockbuster Singulair. The fact that profits beat ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS